Medifast (MED) closed at $12.73 on November 5, 2026, down 3.2% from the previous close, on volume of 149,197 shares (30-day average 126,301).
Data as of November 5, 2026.
Medifast Announces Third Quarter 2026 Financial Results
Business Wire (Mon, 26-Oct 8:05 AM ET)
Why Is Weight Loss Different During Menopause? Common Myths Debunked
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026
Business Wire (Wed, 14-Oct 4:05 PM ET)
5 Questions People Ask When Every Weight Loss Approach Has Failed
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
What Actually Keeps Weight Off After a Weight Loss Program
Globe Newswire (Thu, 8-Oct 7:00 AM ET)
Why Do You Keep Gaining Weight Back After Losing It
Globe Newswire (Tue, 6-Oct 7:00 AM ET)
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Globe Newswire (Thu, 1-Oct 7:00 AM ET)
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update
PRNewswire (Wed, 2-Sep 8:55 AM ET)
Medifast Announces the Launch of the Medifast Metabolic Health Institute
Business Wire (Thu, 27-Aug 8:30 AM ET)
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Medifast trades on the NYSE stock market under the symbol MED.
As of November 6, 2026, MED stock price climbed to $12.78 with 18,253 million shares trading.
MED has a beta of 1.69, meaning it tends to be more sensitive to market movements. MED has a correlation of 0.20 to the broad based SPY ETF.
MED has a market cap of $142.91 million. This is considered a Micro Cap stock.
Last quarter Medifast reported $72 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.17.
In the last 3 years, MED traded as high as $76.42 and as low as $9.22.
The top ETF exchange traded funds that MED belongs to (by Net Assets): AVUV, VTI, DFSV, FNDA, SMLF.
MED has underperformed the market in the last year with a return of +4.9%, while SPY returned +9.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MED shares. However, MED has outperformed the market in the last 3 month and 2 week periods, returning +4.1% and +5.0%, while SPY returned -4.0% and -3.5%, respectively. This indicates MED has been having a stronger performance recently.
MED support price is $12.45 and resistance is $13.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MED shares will trade within this expected range on the day.